Relief for oral pain caused by radiation therapy and chemotherapy for cancer

OncoZenge AB is focused on developing BupiZenge™, a lozenge designed to provide targeted pain relief for patients suffering from oral mucositis, a common and painful side effect of cancer treatments like radiotherapy and chemotherapy. The active ingredient in BupiZenge™ is bupivacaine, a well-researched substance known for its effectiveness in alleviating pain. Clinical studies have demonstrated that this formulation can significantly reduce mouth pain within minutes, offering relief that lasts for hours. This innovative approach addresses a substantial unmet medical need for safe and effective local pain relief, allowing patients to eat and drink without discomfort and potentially reducing their reliance on addictive opioids.

The company is currently advancing BupiZenge™ through clinical trials, having successfully completed phases 1 and 2, and is preparing for phase 3 with the aim of obtaining regulatory approval from agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). OncoZenge AB recognizes the global opportunity presented by the high incidence of oral mucositis among cancer patients, estimating a significant commercial potential in both North America and Europe. By providing a non-opioid alternative for pain management, BupiZenge™ could play a crucial role in addressing the challenges associated with oral pain in cancer care, while also contributing to the ongoing efforts to mitigate the opioid crisis.

Sweden

OncoZenge is developing BupiZenge™, a lozenge based on the safe and effective non-opioid, long acting pain reliever bupivacaine. BupiZenge’s primary indication is oral mucositis and it has the potential to help millions of people with their oral pain caused by radiotherapy and chemotherapy.

OncoZenge AB

Company Details